Standard

Klinicheskie aspekty primeneniia parieta v terapii khronicheskogo pankreatita. / Sablin, O. A.; Ratnikov, V. A.; Butenko, E. V.; Pakhomova, I. G.

In: Ėksperimental'naia i klinicheskaia gastroėnterologiia = Experimental & clinical gastroenterology, No. 5, 01.01.2002.

Research output: Contribution to journal › Article › peer-review

Harvard

Sablin, OA, Ratnikov, VA, Butenko, EV & Pakhomova, IG 2002, 'Klinicheskie aspekty primeneniia parieta v terapii khronicheskogo pankreatita.', Ėksperimental'naia i klinicheskaia gastroėnterologiia = Experimental & clinical gastroenterology, no. 5.

APA

Sablin, O. A., Ratnikov, V. A., Butenko, E. V., & Pakhomova, I. G. (2002). Klinicheskie aspekty primeneniia parieta v terapii khronicheskogo pankreatita. Ėksperimental'naia i klinicheskaia gastroėnterologiia = Experimental & clinical gastroenterology, (5).

Vancouver

Sablin OA, Ratnikov VA, Butenko EV, Pakhomova IG. Klinicheskie aspekty primeneniia parieta v terapii khronicheskogo pankreatita. Ėksperimental'naia i klinicheskaia gastroėnterologiia = Experimental & clinical gastroenterology. 2002 Jan 1;(5).

Author

Sablin, O. A. ; Ratnikov, V. A. ; Butenko, E. V. ; Pakhomova, I. G. / Klinicheskie aspekty primeneniia parieta v terapii khronicheskogo pankreatita. In: Ėksperimental'naia i klinicheskaia gastroėnterologiia = Experimental & clinical gastroenterology. 2002 ; No. 5.

BibTeX

@article{6e9a93c954af4e9ebb0f7c06582c3438,
title = "Klinicheskie aspekty primeneniia parieta v terapii khronicheskogo pankreatita.",
abstract = "Three groups of patients were studied with the purpose of assessing the efficiency of the application of Pariet in the complex treatment of chronic pancreatitis. The first group (16 people) underwent conventional treatment (spasmolytics, enzymes, disintoxication therapy). In addition to conventional treatment, the second (22 people) and third (21 people) groups were administered Pariet (rabeprazole), 20 mg per day, or Quamatel (famotidine), 40 mg per day, respectively. The intragastric and intraduodenal pH was higher against the background of the treatment with Pariet than against the background of the application of Quamatel even within the first hours and days of treatment. A faster pain relief was observed in the second group of patients (p 0.05) than in the third one. According to the MRI data, the seven-day Pariet treatment of patients with chronic pancreatitis was accompanied by a reduction of the pancreas size, the diameter of the main pancreatic duct and the pancreatic edema. Thus, the application of Pariet in the complex treatment of chronic pancreatitis promotes a faster and more efficient pain relief and reduction of pancreatic edemas, as compared to the Quamatel therapy.",
author = "Sablin, {O. A.} and Ratnikov, {V. A.} and Butenko, {E. V.} and Pakhomova, {I. G.}",
year = "2002",
month = jan,
day = "1",
language = "русский",
journal = "Experimental and Clinical Gastroenterology",
issn = "1682-8658",
publisher = "Глобал медиа технологии",
number = "5",

}

RIS

TY - JOUR

T1 - Klinicheskie aspekty primeneniia parieta v terapii khronicheskogo pankreatita.

AU - Sablin, O. A.

AU - Ratnikov, V. A.

AU - Butenko, E. V.

AU - Pakhomova, I. G.

PY - 2002/1/1

Y1 - 2002/1/1

N2 - Three groups of patients were studied with the purpose of assessing the efficiency of the application of Pariet in the complex treatment of chronic pancreatitis. The first group (16 people) underwent conventional treatment (spasmolytics, enzymes, disintoxication therapy). In addition to conventional treatment, the second (22 people) and third (21 people) groups were administered Pariet (rabeprazole), 20 mg per day, or Quamatel (famotidine), 40 mg per day, respectively. The intragastric and intraduodenal pH was higher against the background of the treatment with Pariet than against the background of the application of Quamatel even within the first hours and days of treatment. A faster pain relief was observed in the second group of patients (p 0.05) than in the third one. According to the MRI data, the seven-day Pariet treatment of patients with chronic pancreatitis was accompanied by a reduction of the pancreas size, the diameter of the main pancreatic duct and the pancreatic edema. Thus, the application of Pariet in the complex treatment of chronic pancreatitis promotes a faster and more efficient pain relief and reduction of pancreatic edemas, as compared to the Quamatel therapy.

AB - Three groups of patients were studied with the purpose of assessing the efficiency of the application of Pariet in the complex treatment of chronic pancreatitis. The first group (16 people) underwent conventional treatment (spasmolytics, enzymes, disintoxication therapy). In addition to conventional treatment, the second (22 people) and third (21 people) groups were administered Pariet (rabeprazole), 20 mg per day, or Quamatel (famotidine), 40 mg per day, respectively. The intragastric and intraduodenal pH was higher against the background of the treatment with Pariet than against the background of the application of Quamatel even within the first hours and days of treatment. A faster pain relief was observed in the second group of patients (p 0.05) than in the third one. According to the MRI data, the seven-day Pariet treatment of patients with chronic pancreatitis was accompanied by a reduction of the pancreas size, the diameter of the main pancreatic duct and the pancreatic edema. Thus, the application of Pariet in the complex treatment of chronic pancreatitis promotes a faster and more efficient pain relief and reduction of pancreatic edemas, as compared to the Quamatel therapy.

UR - http://www.scopus.com/inward/record.url?scp=0036976634&partnerID=8YFLogxK

M3 - статья

C2 - 12619583

AN - SCOPUS:0036976634

JO - Experimental and Clinical Gastroenterology

JF - Experimental and Clinical Gastroenterology

SN - 1682-8658

IS - 5

ER -

ID: 39054221